About Market Research Forecast

MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.

Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.

U.S. Orphan Drugs Market

U.S. Orphan Drugs Market Report Probes the USD Billion Size, Share, Growth Report and Future Analysis by 2033

U.S. Orphan Drugs Market by Therapy Area (Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy, Others), by Drug Type (Biologics, Non-Biologics), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Forecast 2026-2034

Jun 5 2025

Base Year: 2025

180 Pages

U.S. Orphan Drugs Market Report Probes the USD Billion Size, Share, Growth Report and Future Analysis by 2033

Key Insights

The U.S. Orphan Drugs Market size was valued at USD 77.82 USD Billion in 2023 and is projected to reach USD 170.96 USD Billion by 2032, exhibiting a CAGR of 11.9 % during the forecast period. The US Orphan Drug Market is meant for rare diseases that are not heavily spread out and diagnosed in a tiny percentage of the population. These drugs, which are on the orphan drug list because the market size of the disease that they treat is very small, are very important in the treatment of patients with rare diseases who have no other treatment options. Orphan drugs refer to medicines that are being used in various therapeutic problems such as genetic diseases, rare cancers, and rare metabolic disorders. The three vital areas in these procedures are disease control, symptom relief, and curative treatment in some of the cases. The orphan drug market is a spectrum of the increase in orphan drug research and development, the fast-tracked approval by the regulatory agencies, the growing collaboration among the pharmaceutical companies, the patient advocacy groups, and the regulatory agencies that are the factors that lead to the faster access to the new therapies for rare diseases in the United States.

U.S. Orphan Drugs Trends

Growing focus on personalized medicine
Increasing prevalence of rare diseases
Government initiatives to support orphan drug development
Advancements in gene therapy and stem cell therapy

U.S. Orphan Drugs Market Market Size and Forecast (2024-2030) — U.S. Orphan Drugs Market Company Market Share

Driving Forces: What's Propelling the U.S. Orphan Drugs Market

Government Incentives: The U.S. government provides substantial support for orphan drug development through various programs. These include significant tax credits, substantial research grants, and expedited FDA approval pathways (e.g., Orphan Drug Designation, Breakthrough Therapy Designation), reducing the time and financial burden associated with bringing these treatments to market. This incentivizes pharmaceutical companies to invest in research and development for rare diseases.
Rising Prevalence of Rare Diseases: While individually rare, collectively, rare diseases affect a substantial portion of the population. Advancements in diagnostics, including genetic testing and improved screening technologies, have led to a significant increase in the identification and diagnosis of these previously overlooked conditions, creating a larger patient pool requiring treatment.
Advancements in Biotechnology and Therapeutics: The field of biotechnology is rapidly evolving, offering novel treatment approaches for rare diseases. Gene therapies, including CRISPR-Cas9 gene editing and other gene-editing techniques, along with advanced stem cell therapies and highly targeted therapies, offer hope for previously untreatable conditions. These advancements translate into a robust pipeline of promising new orphan drugs.
Patient Advocacy Groups and Increased Awareness: Strong and active patient advocacy groups play a crucial role in driving the orphan drug market. These organizations advocate tirelessly for increased research funding, improved access to treatment, patient support services, and greater awareness of rare diseases among healthcare professionals and the general public. Their influence shapes policy and accelerates progress.
High Pricing Strategies and Market Exclusivity: The Orphan Drug Act grants seven years of market exclusivity to approved orphan drugs. This, combined with the often high price point of these specialized medications, contributes to the market's overall value. However, this also raises concerns regarding affordability and access for patients.

Challenges and Restraints in U.S. Orphan Drugs Market

High Development Costs: R&D costs for orphan drugs remain high, primarily due to the complex nature of clinical trials and the limited patient population available for recruitment.
Limited Market Size: The small patient population for orphan diseases creates a limited market size, making commercial viability challenging for drug manufacturers.
Reimbursement Challenges: Payers often face difficulties in assessing the cost-effectiveness of orphan drugs, leading to reimbursement barriers for these high-cost therapies.

Emerging Trends in U.S. Orphan Drugs

Precision Medicines: Targeting specific genetic mutations and biomarkers for more effective treatments.
Patient-Focused Development: Involving patients in clinical trials and research to improve outcomes and acceptability.
Digital Health Integration: Technology-enabled tools for patient support, monitoring, and data collection.

Growth Catalysts in U.S. Orphan Drugs Industry

Government Support: Continued incentives and funding for orphan drug development.
Technological Advancements: Innovation in drug discovery and delivery systems.
Increasing Collaboration: Partnerships between pharmaceutical companies, researchers, and patient organizations.

Market Segmentation: U.S. Orphan Drugs Analysis

Therapy Area:

Oncology
Hematology
Neurology
Endocrinology
Cardiovascular
Respiratory
Immunotherapy
Others

Drug Type:

Biologics
Non-Biologics

Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Leading Players in the U.S. Orphan Drugs Market

Significant developments in U.S. Orphan Drugs Sector

April 2023 – Biogen received FDA approval for QALSODY (tofersen) for treating amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.
March 2023 – Pharming Group N.V. received FDA approval for Joenja (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients 12 years of age and older.
February 2023 – Travere Therapeutics, Inc. received accelerated approval from the U.S. FDA for FILSPARI (sparsentan), the non-immunosuppressive therapy that is indicated to reduce proteinuria in adults with immunoglobulin A nephropathy (IgAN).

Comprehensive Coverage U.S. Orphan Drugs Market Report

Market Outlook: Historical and future market size, growth trends, and competitive landscape.
Market Drivers and Challenges: Factors influencing market growth and barriers to entry.
Market Segmentation: Analysis by therapy area, drug type, and distribution channel.
Competitive Landscape: Profiles of leading players, market shares, and product portfolios.
Industry Developments: Regulatory changes, clinical trials, and advancements in technology.

Regional Insight

North America (U.S., Canada): North America, particularly the United States, remains the dominant force in the global orphan drug market. This leadership position is driven by a robust research and development infrastructure, a favorable regulatory environment that supports innovation, significant investments in healthcare, and a high concentration of pharmaceutical companies specializing in rare disease treatments.
Europe (Germany, France, U.K.): Europe represents a substantial market for orphan drugs, characterized by well-established healthcare systems, relatively strong reimbursement policies for approved therapies, and a growing awareness of rare diseases among healthcare professionals and patients. However, variations in regulatory processes and reimbursement models across different European countries can impact market access.
Asia-Pacific (China, Japan, India): The Asia-Pacific region is an emerging and rapidly expanding market for orphan drugs. Growing awareness of rare diseases, increasing disposable income in certain segments, and government initiatives to improve healthcare infrastructure are contributing factors. However, challenges remain, including regulatory hurdles and variations in healthcare access across different countries within the region.
Latin America (Brazil, Mexico): Latin America presents an expanding market with significant potential. Improvements in healthcare infrastructure and increased access to advanced therapies are driving growth. However, challenges related to affordability and healthcare disparities across different socioeconomic groups persist.
Middle East and Africa (Saudi Arabia, UAE, South Africa): The Middle East and Africa remain relatively underdeveloped markets for orphan drugs, primarily due to limited healthcare infrastructure, reimbursement challenges, and lower awareness of rare diseases. However, some pockets of growth exist in wealthier nations with more advanced healthcare systems.

U.S. Orphan Drugs Market Market Share by Region - Global Geographic Distribution — U.S. Orphan Drugs Market Regional Market Share

DROCT

Orphan drugs are designed to treat rare diseases affecting fewer than 200,000 people in the U.S.
The Orphan Drug Act of 1983 provides incentives for the development of orphan drugs.
The FDA grants Orphan Drug Designation (ODD) to drugs that meet certain criteria.

Pricing Analysis

Orphan drugs often command premium prices due to high research and development costs and limited market size.
Government programs, such as Medicare Part B, provide coverage for orphan drugs.

Import And Export Analysis

The U.S. imports a significant portion of orphan drugs from other countries.
Exports of orphan drugs from the U.S. are growing due to increased global demand.

Segmentation

By Therapy Area:

Oncology
Hematology
Neurology
Endocrinology
Cardiovascular
Respiratory
Immunotherapy
Others

By Drug Type:

Biologics
Non-Biologics

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Patent/Trademark Analysis

Orphan drugs are typically protected by patents and trademarks.
Patent protection gives exclusive rights to develop, manufacture, and sell the drug for a limited period.
Trademark protection ensures the unique identity and branding of the drug.

U.S. Orphan Drugs Market REPORT HIGHLIGHTS

Aspects	Details
Study Period	2020-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2020-2025
Growth Rate	CAGR of 11.9% from 2020-2034
Segmentation	By Therapy Area Oncology Hematology Neurology Endocrinology Cardiovascular Respiratory Immunotherapy Others By Drug Type Biologics Non-Biologics By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies By Geography

1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
- 2.1. Introduction
3. Market Dynamics
- 3.1. Introduction
- - 3.2. Market Drivers
  - - 3.2.1. Increasing Prevalence of Respiratory Diseases to Drive Market Growth
- - 3.3. Market Restrains
  - - 3.3.1. Limited Product Adoption Owing to High Cost May Hinder the Market Growth
- - 3.4. Market Trends
  - - 3.4.1. Increasing Number of Hospitals and ASCs Identified as Significant Market Trend
4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
5. U.S. Orphan Drugs Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Therapy Area
  - 5.1.1. Oncology
  - 5.1.2. Hematology
  - 5.1.3. Neurology
  - 5.1.4. Endocrinology
  - 5.1.5. Cardiovascular
  - 5.1.6. Respiratory
  - 5.1.7. Immunotherapy
  - 5.1.8. Others
- 5.2. Market Analysis, Insights and Forecast - by Drug Type
  - 5.2.1. Biologics
  - 5.2.2. Non-Biologics
- 5.3. Market Analysis, Insights and Forecast - by Distribution Channel
  - 5.3.1. Hospital Pharmacies
  - 5.3.2. Retail Pharmacies
  - 5.3.3. Online Pharmacies
- 5.4. Market Analysis, Insights and Forecast - by Region
  - 5.4.1.
6. Competitive Analysis
- 6.1. Market Share Analysis 2025
- - 6.2. Company Profiles
  - - 6.2.1 Amgen Inc. (U.S.)
      6.2.1.1. Overview
      6.2.1.2. Products
      6.2.1.3. SWOT Analysis
      6.2.1.4. Recent Developments
      6.2.1.5. Financials (Based on Availability)
    - 6.2.2 Bayer AG (Germany)
      6.2.2.1. Overview
      6.2.2.2. Products
      6.2.2.3. SWOT Analysis
      6.2.2.4. Recent Developments
      6.2.2.5. Financials (Based on Availability)
    - 6.2.3 F. Hoffmann-La Roche Ltd (Switzerland)
      6.2.3.1. Overview
      6.2.3.2. Products
      6.2.3.3. SWOT Analysis
      6.2.3.4. Recent Developments
      6.2.3.5. Financials (Based on Availability)
    - 6.2.4 Alexion Pharmaceuticals Inc. (U.S.)
      6.2.4.1. Overview
      6.2.4.2. Products
      6.2.4.3. SWOT Analysis
      6.2.4.4. Recent Developments
      6.2.4.5. Financials (Based on Availability)
    - 6.2.5 Novo Nordisk A/S (Denmark)
      6.2.5.1. Overview
      6.2.5.2. Products
      6.2.5.3. SWOT Analysis
      6.2.5.4. Recent Developments
      6.2.5.5. Financials (Based on Availability)
    - 6.2.6 Novartis AG (Switzerland)
      6.2.6.1. Overview
      6.2.6.2. Products
      6.2.6.3. SWOT Analysis
      6.2.6.4. Recent Developments
      6.2.6.5. Financials (Based on Availability)
    - 6.2.7 Bristol-Myers Squibb Company (U.S.)
      6.2.7.1. Overview
      6.2.7.2. Products
      6.2.7.3. SWOT Analysis
      6.2.7.4. Recent Developments
      6.2.7.5. Financials (Based on Availability)
    - 6.2.8 AstraZeneca (U.K.)
      6.2.8.1. Overview
      6.2.8.2. Products
      6.2.8.3. SWOT Analysis
      6.2.8.4. Recent Developments
      6.2.8.5. Financials (Based on Availability)
    - 6.2.9 DAIICHI SANKYO COMPANY LIMITED (Japan)
      6.2.9.1. Overview
      6.2.9.2. Products
      6.2.9.3. SWOT Analysis
      6.2.9.4. Recent Developments
      6.2.9.5. Financials (Based on Availability)
    - 6.2.10 GlaxoSmithKline plc (U.K.)
      6.2.10.1. Overview
      6.2.10.2. Products
      6.2.10.3. SWOT Analysis
      6.2.10.4. Recent Developments
      6.2.10.5. Financials (Based on Availability)

List of Figures

Figure 1: U.S. Orphan Drugs Market Revenue Breakdown (USD Billion, %) by Product 2025 & 2033
Figure 2: U.S. Orphan Drugs Market Share (%) by Company 2025

List of Tables

Table 1: U.S. Orphan Drugs Market Revenue USD Billion Forecast, by Therapy Area 2020 & 2033
Table 2: U.S. Orphan Drugs Market Volume K Tons Forecast, by Therapy Area 2020 & 2033
Table 3: U.S. Orphan Drugs Market Revenue USD Billion Forecast, by Drug Type 2020 & 2033
Table 4: U.S. Orphan Drugs Market Volume K Tons Forecast, by Drug Type 2020 & 2033
Table 5: U.S. Orphan Drugs Market Revenue USD Billion Forecast, by Distribution Channel 2020 & 2033
Table 6: U.S. Orphan Drugs Market Volume K Tons Forecast, by Distribution Channel 2020 & 2033
Table 7: U.S. Orphan Drugs Market Revenue USD Billion Forecast, by Region 2020 & 2033
Table 8: U.S. Orphan Drugs Market Volume K Tons Forecast, by Region 2020 & 2033
Table 9: U.S. Orphan Drugs Market Revenue USD Billion Forecast, by Therapy Area 2020 & 2033
Table 10: U.S. Orphan Drugs Market Volume K Tons Forecast, by Therapy Area 2020 & 2033
Table 11: U.S. Orphan Drugs Market Revenue USD Billion Forecast, by Drug Type 2020 & 2033
Table 12: U.S. Orphan Drugs Market Volume K Tons Forecast, by Drug Type 2020 & 2033
Table 13: U.S. Orphan Drugs Market Revenue USD Billion Forecast, by Distribution Channel 2020 & 2033
Table 14: U.S. Orphan Drugs Market Volume K Tons Forecast, by Distribution Channel 2020 & 2033
Table 15: U.S. Orphan Drugs Market Revenue USD Billion Forecast, by Country 2020 & 2033
Table 16: U.S. Orphan Drugs Market Volume K Tons Forecast, by Country 2020 & 2033

Methodology

Step 1 - Identification of Relevant Samples Size from Population Database

Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.

Note*: In applicable scenarios

Step 3 - Data Sources

Primary Research

Web Analytics
Survey Reports
Research Institute
Latest Research Reports
Opinion Leaders

Secondary Research

Annual Reports
White Paper
Latest Press Release
Industry Association
Paid Database
Investor Presentations

Step 4 - Data Triangulation

Involves using different sources of information in order to increase the validity of a study

These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.

Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.

During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence

Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.

Frequently Asked Questions

1. What is the projected Compound Annual Growth Rate (CAGR) of the U.S. Orphan Drugs Market?

The projected CAGR is approximately 11.9%.

2. Which companies are prominent players in the U.S. Orphan Drugs Market?

Key companies in the market include Amgen Inc. (U.S.), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Alexion Pharmaceuticals Inc. (U.S.), Novo Nordisk A/S (Denmark), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), AstraZeneca (U.K.), DAIICHI SANKYO COMPANY, LIMITED (Japan), GlaxoSmithKline plc (U.K.).

3. What are the main segments of the U.S. Orphan Drugs Market?

The market segments include Therapy Area, Drug Type, Distribution Channel.

4. Can you provide details about the market size?

The market size is estimated to be USD 77.82 USD Billion as of 2022.

5. What are some drivers contributing to market growth?

Increasing Prevalence of Respiratory Diseases to Drive Market Growth.

6. What are the notable trends driving market growth?

Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.

7. Are there any restraints impacting market growth?

Limited Product Adoption Owing to High Cost May Hinder the Market Growth.

8. Can you provide examples of recent developments in the market?

April 2023 – Biogen received FDA approval for QALSODY (tofersen) for treating amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

9. What pricing options are available for accessing the report?

Pricing options include single-user, multi-user, and enterprise licenses priced at USD 2850, USD 3850, and USD 4850 respectively.

10. Is the market size provided in terms of value or volume?

The market size is provided in terms of value, measured in USD Billion and volume, measured in K Tons.

11. Are there any specific market keywords associated with the report?

Yes, the market keyword associated with the report is "U.S. Orphan Drugs Market," which aids in identifying and referencing the specific market segment covered.

12. How do I determine which pricing option suits my needs best?

The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.

13. Are there any additional resources or data provided in the U.S. Orphan Drugs Market report?

While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.

14. How can I stay updated on further developments or reports in the U.S. Orphan Drugs Market?

To stay informed about further developments, trends, and reports in the U.S. Orphan Drugs Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.

Get Free Sample

Pre Order Enquiry Request discount

Pricing

Related Reports

Orphan Drugs Market Future-proof Strategies: Trends, Competitor Dynamics, and Opportunities 2025-2033

Orphan Drug Development XX CAGR Growth Outlook 2025-2033

Orphan Drugs Service Unlocking Growth Potential: Analysis and Forecasts 2025-2033

Orphan Drugs for Adults Analysis Report 2025: Market to Grow by a CAGR of 9.2 to 2033, Driven by Government Incentives, Popularity of Virtual Assistants, and Strategic Partnerships

Orphan Drugs 9.6 CAGR Growth Outlook 2025-2033

Tailored for you

In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions
Customized Evaluation of Competitive Landscape to Meet Your Needs
Tailored Customization to Address Other Specific Requirements

Ask for customization

The response was good, and I got what I was looking for as far as the report. Thank you for that.

Erik Perison

US TPS Business Development Manager at Thermon

As requested- presale engagement was good, your perseverance, support and prompt responses were noted. Your follow up with vm’s were much appreciated. Happy with the final report and post sales by your team.

Shankar Godavarti

Global Product, Quality & Strategy Executive- Principal Innovator at Donaldson

I have received the report already. Thanks you for your help.it has been a pleasure working with you. Thank you againg for a good quality report